Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Short Interest Update

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 472,300 shares, an increase of 96.5% from the January 15th total of 240,300 shares. Based on an average daily trading volume, of 624,300 shares, the short-interest ratio is currently 0.8 days. Currently, 7.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Bullfrog AI

Several hedge funds and other institutional investors have recently bought and sold shares of BFRG. Two Sigma Securities LLC acquired a new position in Bullfrog AI in the fourth quarter valued at $41,000. Raymond James Financial Inc. acquired a new position in shares of Bullfrog AI during the fourth quarter valued at about $30,000. Finally, Geode Capital Management LLC raised its holdings in shares of Bullfrog AI by 31.0% during the fourth quarter. Geode Capital Management LLC now owns 47,093 shares of the company’s stock valued at $94,000 after purchasing an additional 11,140 shares during the period. Institutional investors and hedge funds own 0.96% of the company’s stock.

Bullfrog AI Trading Down 7.8 %

BFRG stock traded down $0.31 during midday trading on Friday, hitting $3.65. The stock had a trading volume of 3,092,253 shares, compared to its average volume of 500,691. The firm has a market cap of $31.79 million, a P/E ratio of -4.29 and a beta of 0.18. Bullfrog AI has a 1-year low of $1.43 and a 1-year high of $5.52. The business has a fifty day moving average price of $2.41 and a two-hundred day moving average price of $2.46.

Bullfrog AI Company Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.